News

Feb 2023
Publication First in Human study

Online publication on LiGalli’s First in Human oxybutynin MedRing study showing favorable vaginal absorption and  pharmacokinetics.

Sep 2022
Appointment of Unilever veteran Marga Mathijssen as CEO of LiGalli

See press release here.

Apr 2022
First patent granted in Japan

Certificate of patent.

Jan 2022
LiGalli raises €6.6 million​ in Series B

The LiGalli press release can be found here.

Dec 2021
Development partner Demcon published an article on LiGalli in their internal Demcon Investment newsletter

Read the article here.

Sept 2021
LiGalli receives the International Life Sciences Award 2021

Read the article here.

Apr 2021
The basic MedRing patent is granted in China
Feb 2021
Stunning results LiGalli first in human study

See press release here.

Nov 2020
LiGalli receives the International Life Sciences Award 2020

See an image of the award here. Read the interview with LiGalli's CEO here.

Sept 2020
The MedRing Alpha 1.0 is ready

The first in-human trials will start shortly.

June 2020
LiGalli raises €6 million

The LiGalli press release can be found here. The Demcon press release can be found here.

March 2020
The basic MedRing patent is granted

First in the EU, later also in the US

Feb 2020
The MedRing functional model is ready

Watch the video on the page “How it works.”

Dec 2019
The Dutch Government awards LiGalli the MIT subsidy

We look forward to working with our new partner Gimix ('TwentyNext' per July 2022).

What's new

If you had to guess, which is more common in women—diabetes or endometriosis? It’s a trick question. They actually affect women equally. However, endometriosis receives $1 of research funding for every $200 invested in diabetes. 

While there may be various explanations for this discrepancy, there’s a long pattern of health care providers, venture capitalists, and science…

Get in touch

Office
Leiden Bio Science Park – BioPartner 1

Address
J.H. Oortweg 21
2333 CH Leiden
The Netherlands